Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Blackstone, Novartis spin out cardiovascular newco Anthos

Leading its first deal since acquiring Clarus Ventures, Blackstone has partnered with Novartis AG (NYSE:NVS; SIX:NOVN) to launch Anthos Therapeutics Inc. (Cambridge, Mass.) with $250 million and Novartis antithrombotic MAA868.

In exchange for

Read the full 324 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers